![Uma Sinha](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 54 900 $ al 31/05/2026
En la actualidad, Uma Sinha ocupa el cargo de directora científica de BridgeBio Pharma, Inc. y directora científica de Eidos Therapeutics, Inc. (una filial de BridgeBio Pharma, Inc.). Anteriormente, la Dra. Sinha ocupó el cargo de Directora Científica de Global Blood Therapeutics, Inc., Directora de COR Therapeutics, Inc., Directora Senior-Cardiovascular de Millennium Pharmaceuticals, Inc., Directora de Genencor International, Inc. y Vicepresidenta y Jefa de Biología de Portola Pharmaceuticals, Inc. Se doctoró en la Universidad de Georgia y se licenció en el Presidency College.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
PROKIDNEY CORP. CLASS A 0,02 % | 28/05/2026 | 30.000 ( 0,02 % ) | 54 900 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| EIDOS THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 01/06/2016 |
| BRIDGEBIO PHARMA, INC. | Director Técnico/Científico/I+D | 01/04/2016 |
| PROKIDNEY CORP. | Director/Miembro de la Junta | 01/07/2022 |
| Empresas | Cargo | Fin |
|---|---|---|
| GLOBAL BLOOD THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 01/06/2015 |
| PORTOLA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/12/2012 |
COR Therapeutics, Inc.
 COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops biopharmaceutical products for acute cardiovascular diseases | Corporate Officer/Principal | 01/01/2002 |
| PROKIDNEY A | Director/Miembro de la Junta | - |
Genencor International, Inc.
 Genencor International, Inc. BiotechnologyHealth Technology Develops and manufactures enzyme product solutions | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 11 |
|---|---|
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops biopharmaceutical products for acute cardiovascular diseases | Health Technology |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment | Health Technology |
Genencor International, Inc.
Genencor International, Inc. BiotechnologyHealth Technology Develops and manufactures enzyme product solutions | Health Technology |
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of novel therapeutics | Health Technology |
University of Georgia
 University of Georgia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Presidency College
 Presidency College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which provides treatment and care of sickle cell disease for inherited blood disorder | Health Technology |
Eidos Therapeutics, Inc.
 Eidos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
BridgeBio Pharma, Inc.
 BridgeBio Pharma, Inc. BiotechnologyHealth Technology Develops medicines for genetic diseases to patients | Health Technology |
Social Capital Suvretta Holdings Corp. III
 Social Capital Suvretta Holdings Corp. III Financial ConglomeratesFinance Operates as a blank check company | Finance |
ProKidney Corp.
 ProKidney Corp. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
